Photopharmics has completed enrollment of a Phase 3 clinical trial testing Celeste, its light therapy device for Parkinson’s disease, the company announced. The ongoing Phase 3 trial (NCT04453033), dubbed Light for PD, has enrolled 350 participants with Parkinson’s, surpassing the initial target enrollment of 300 patients. Topline results…
A $1.9 million U.S. Department of Defense–funded Phase 2 clinical trial will test SwallowFIT, a targeted exercise program designed to retrain the brain’s ability to control the muscles involved in swallowing — a function often compromised in Parkinson’s disease — in active-duty service members, veterans, or their relatives who…
Jotrol, an oral formulation of the natural compound resveratrol, has been cleared for testing in people with Parkinson’s disease by the U.S. Food and Drug Administration (FDA). Jupiter Neurosciences will conduct the Phase 2a clinical trial with Zina Biopharmaceuticals to evaluate the safety, tolerability, and pharmacological properties…
Women with isolated REM sleep behavior disorder (iRBD), an early sign of Parkinson’s disease, exhibit fewer signs of early brain deterioration than men of similar age and disease severity, a study showed. The study, which analyzed the brains of almost 700 people with iRBD and healthy controls, found that women…
Most molecular features in the human brain differ between samples obtained from living individuals and those collected after death, according to new findings from the Living Brain Project, a multiscale investigation from The Friedman Brain Institute in New York. This study, led by researchers at the Icahn School of…
People with Parkinson’s disease have an increased abundance of the oral bacteria Streptococcus mutans — typically found in the mouth and associated with cavities in the teeth — in their gut, according to a new study involving patients and a mouse model. Once established in the gut, these bacteria…
Irlab Therapeutics has announced new advancements for its three symptoms-targeting Parkinson’s disease drugs — medications designed to treat apathy, prevent falls, and reduce uncontrolled movements, known as dyskinesia, among people with the neurodegenerative disease. Before the year’s end, the company intends to launch a Phase 1b clinical trial…
More than half of people with Parkinson’s disease take nutritional supplements, a study found. Yet fewer than half discuss them with their doctors. Almost one in three Parkinson’s patients use other forms of complementary and alternative medicine (CAM) alongside their standard treatment, the study found. Both practices are more…
CND Life Sciences has been awarded a $3 million grant from the U.S. National Institutes of Health (NIH) to evaluate whether its skin test can predict the risk of Parkinson’s disease in people with essential tremor. The three-year Small Business Innovation Research grant will support a study aimed…
A Phase 2 clinical trial evaluating Avextra’s cannabis-based oral solution’s safety and efficacy in people with Parkinson’s disease and other neurodegenerative disorders has enrolled its first patient. The medicine used in the NEUROBIS (EUCT 2023-507715-35-02) clinical trial is described as a full-spectrum cannabis extract, meaning it contains…
Get regular updates to your inbox.
